氧化应激调控肌少症发病机制及其中西药物靶向干预研究进展  

Oxidative Stress Regulates the Pathogenesis of Sarcopenia and Its Research Progress on Targeted Intervention of Chinese and Western Drugs

作　　者：韦继婵 刘雪辉[2] 

机构地区：[1]成都中医药大学临床医学院,四川 成都 [2]成都中医药大学附属医院老年科,四川 成都

出　　处：《临床医学进展》2025年第2期1341-1349,共9页Advances in Clinical Medicine

摘　　要：肌少症(sarcopenia)是一种以肌肉量减少、肌肉质量和力量下降、躯体功能减退为特征的老年综合征。由于老龄化程度的增加,肌少症已成为一个重大的社会经济负担。肌少症发病机制复杂,大量研究发现氧化应激可能是肌少症发生的重要机制之一。尽管目前还没有特定的药物被批准用于治疗肌少症,但也有一些药物干预可改善肌少症,多数可能治疗肌少症的药物尚处于研发阶段。本文针对肌少症氧化应激发病机制及治疗靶点对肌少症药物治疗的最新研究进展进行总结综述,期望为肌少症药物治疗及新药研发提供参考。Sarcopenia is an age-related syndrome characterized by reduced muscle mass, decreased muscle quality and strength, and impaired physical function. Due to the increasing degree of aging, sarcopenia has become a significant socioeconomic burden. The pathogenesis of sarcopenia is complex, and numerous studies have found that oxidative stress may be one of the important mechanisms underlying its occurrence. Although no specific drugs have been approved for the treatment of sarcopenia yet, some drug interventions can improve sarcopenia, and most of the potential drugs for treating sarcopenia are still in the research and development stage. This article summarizes and reviews the latest research progress on the oxidative stress pathogenesis and therapeutic targets of sarcopenia for drug treatment, hoping to provide references for the drug treatment of sarcopenia and the development of new drugs.

关 键 词：肌少症 药物治疗 氧化应激 

分 类 号：R87[医药卫生—运动医学]